Iterum Therapeutics plc Receives Nasdaq Delisting Notice, Requests Hearing to Appeal

Key Developments and Potential Impact on Shareholders

Iterum Therapeutics plc (“the Company”) has disclosed significant developments regarding its listing status on The Nasdaq Stock Market LLC, which are likely to be of major interest to current and prospective shareholders.

1. Nasdaq Delisting Determination Letter

• On February 24, 2026, Iterum Therapeutics received a delisting determination letter from Nasdaq. The reason for the notice is the Company’s failure to maintain a minimum bid price of \$1.00 per share, as required under the Nasdaq Capital Market’s continued listing rules (the “Bid Price Rule”).
• Nasdaq indicated that, as a result of this deficiency, the Company’s ordinary shares are scheduled for delisting and will be suspended from trading on Nasdaq effective at the open of business on March 5, 2026, unless the Company requests a hearing before an independent Nasdaq Hearings Panel.

2. Company’s Response: Hearing Requested

• On March 3, 2026, Iterum Therapeutics formally requested a hearing before the Panel. As per Nasdaq rules, this request automatically stays any suspension or delisting action pending the hearing and any possible extension period granted by the Panel.
• This means the Company’s shares will continue to trade on Nasdaq until a decision is made post-hearing.

3. Additional Nasdaq Compliance Issues

• Separately, Iterum is also not in compliance with Nasdaq Listing Rule 5550(b)(2), which mandates a minimum market value of listed securities (“Minimum MVLS Requirement”) of \$35 million for continued listing.
• The Company has until June 9, 2026 to regain compliance with the Minimum MVLS Requirement. At the upcoming hearing, Iterum must demonstrate its ability to achieve and sustain compliance with this requirement by the deadline, or risk delisting.
• Iterum also does not meet alternative listing requirements related to minimum shareholders’ equity or net income.

4. Corporate, Strategic, and Financial Alternatives under Consideration

• Due to its ongoing compliance challenges and its limited ability to raise additional capital, Iterum Therapeutics is actively evaluating a range of corporate, strategic, and financial alternatives.
• These alternatives include:
  • The possibility of winding down company operations.
  • The potential commencement of bankruptcy, liquidation, dissolution, or similar proceedings. In such an outcome, shareholders would be very unlikely to receive any meaningful distribution or return on their investment.
  • The licensing, sale, or divestiture of the Company’s assets or proprietary technologies.
  • Other strategic transactions involving the Company.
• The Company notes that its limited time and resources may constrain its ability to identify, evaluate, and complete any strategic transaction.
• The evaluation of these alternatives may not result in any particular action or transaction being pursued, entered into, or completed. There is no assurance on the timing or outcome of any such actions.

5. Forward-Looking Statements and Risks

• The Company emphasizes that its ability to successfully appeal the Nasdaq delisting determination, regain compliance with all Nasdaq listing requirements, or complete any strategic transaction is subject to significant uncertainty and risks.
• Actual future outcomes may differ materially from current expectations, especially with respect to the possible delisting, execution of strategic alternatives, or shareholder recoveries in a wind-down or bankruptcy scenario.
• Shareholders are urged to review the Company’s risk factors as detailed in its most recent quarterly and other filings with the SEC for more information on these and other risks.

Summary for Investors

This announcement is highly price-sensitive. Iterum Therapeutics faces imminent delisting from Nasdaq due to failing minimum bid price and market value requirements, unless it can prevail at an upcoming Nasdaq Panel hearing. The Company is also candid about the possibility of a wind-down, bankruptcy, or asset sale, with a strong warning that shareholders are unlikely to receive any meaningful value in such scenarios. The situation is dynamic, and the outcome of the hearing, as well as the Company’s ability to secure strategic alternatives, remains highly uncertain.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consider all risk factors and consult professional advisors before making any investment decisions. The situation described is fluid and subject to change, and no assurance can be given regarding the Company’s ability to remain listed, regain compliance, or deliver any value to shareholders.

View Iterum Therapeutics plc Historical chart here